Patient Support

Co-pay assistance for ZEMBRACE SymTouch

The Dual Savings Card* can help patients save

Zembrace Dual Savings Card Image
Eligibility Rules
*See card for details. Limitations apply. Each box contains 4 single-use injections. A prescription may be more than 1 box.
Co-pay offer on generic sumatriptan only applies to the patients who receive a prescription from their doctor for both oral medications as well as ZEMBRACE SymTouch.

Putting patients first

Talk to your ZEMBRACE SymTouch representative about these programs today!

Getting started is easy:
  1. Prescribe
      Prescribe ZEMBRACE SymTouch through
      Direct Success Pharmacy
    • Phone: 888-959-7600, Fax: 855-345-6789
    • ePrescribe to Direct Success Pharmacy: ZIP code 07727
    • Hours Mon-Fri 8 AM to 9 PM ET, Sat 9 AM to 3 PM ET
    • Direct Success Pharmacy delivers to the contiguous
      United States
  2. Patient-Pharmacy Contact
      Encourage your patients to call Direct Success Pharmacy at 1-888-959-7600 to:
    • Determine insurance coverage
    • Find ways to minimize out-of-pocket costs
    • Arrange free shipping
    • If Direct Success Pharmacy doesn't hear from your patient within 24 hours, they will call the number you provided
  3. Assurance If your patient runs into challenges with insurance coverage, eligible commercially insured patients may qualify to receive a free trial

IMPORTANT SAFETY INFORMATION

ZEMBRACE SymTouch is contraindicated in patients with:
  • Ischemic Coronary Artery Disease (CAD) or coronary artery vasospasm (including Prinzmetal’s angina), Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
  • Uncontrolled hypertension, history of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine
  • Peripheral vascular disease
  • Ischemic bowel disease
  • Recent (i.e., within 24 hours) use of ergotamine-containing medication, ergot derivatives, or another 5-HT1 agonist
  • Concurrent or recent (within 2 weeks) use of an MAO-A inhibitor
  • Known hypersensitivity to sumatriptan
  • Severe hepatic impairment

There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of sumatriptan injection. Some of these reactions occurred in patients without known CAD. 5-HT1 agonists, including ZEMBRACE SymTouch, may cause coronary artery vasospasm. Life-threatening disturbances of cardiac rhythm leading to death in some cases, have been reported within a few hours following the administration of 5-HT1 agonists. Cerebrovascular events including cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists, and some have resulted in fatalities. Discontinue ZEMBRACE SymTouch if any of these events occur.

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors prior to receiving ZEMBRACE SymTouch. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first dose of ZEMBRACE SymTouch in a medically supervised setting and consider periodic follow up. Sensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw commonly occur after treatment with sumatriptan injection and are usually non-cardiac in origin.

ZEMBRACE SymTouch may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction, splenic infarction, and Raynaud’s syndrome. Overuse of acute migraine drugs may lead to exacerbation of headache (medication overuse headache). Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms may be necessary.

Serotonin syndrome may occur with ZEMBRACE SymTouch, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors. Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT1 agonists, including patients without a history of hypertension. Monitor blood pressure in patients treated with ZEMBRACE SymTouch. Discontinue ZEMBRACE SymTouch if serotonin syndrome is suspected or hypertensive crisis is observed.

Seizures have been reported following administration of sumatriptan. Some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures. ZEMBRACE SymTouch should be used with caution in patients with a history of epilepsy or conditions associated with a lowered seizure threshold.

Most common adverse reactions (≥5% and > placebo) were injection site reactions, tingling, dizziness/vertigo, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, flushing, feeling of tightness, and numbness.

These are not all the side effects associated with ZEMBRACE SymTouch. Advise the patient to read the FDA-approved patient labeling. Please see Patient Information, Instructions For Use and Full Prescribing Information for ZEMBRACE SymTouch at www.ZEMBRACE.com.

You are encouraged to report negative side effects of prescription drugs. To report SUSPECTED SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at 1-800-FDA-1088 (1-800-332-1088) or online at http://www.fda.gov/Safety/MedWatch

INDICATION AND USAGE

ZEMBRACE SymTouch is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use:
  • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with ZEMBRACE SymTouch, reconsider the diagnosis before ZEMBRACE SymTouch is administered to treat any subsequent attacks.
  • ZEMBRACE SymTouch is not indicated for the prevention of migraine attacks.

IMPORTANT SAFETY INFORMATION

ZEMBRACE SymTouch is contraindicated in patients with:
  • Ischemic Coronary Artery Disease (CAD) or coronary artery vasospasm (including Prinzmetal’s angina), Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
  • Uncontrolled hypertension, history of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine
  • Peripheral vascular disease
  • Ischemic bowel disease
  • Recent (i.e., within 24 hours) use of ergotamine-containing medication, ergot derivatives, or another 5-HT1 agonist
  • Concurrent or recent (within 2 weeks) use of an MAO-A inhibitor
  • Known hypersensitivity to sumatriptan
  • Severe hepatic impairment

There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of sumatriptan injection. Some of these reactions occurred in patients without known CAD. 5-HT1 agonists, including ZEMBRACE SymTouch, may cause coronary artery vasospasm. Life-threatening disturbances of cardiac rhythm leading to death in some cases, have been reported within a few hours following the administration of 5-HT1 agonists. Cerebrovascular events including cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists, and some have resulted in fatalities. Discontinue ZEMBRACE SymTouch if any of these events occur.

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors prior to receiving ZEMBRACE SymTouch. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first dose of ZEMBRACE SymTouch in a medically supervised setting and consider periodic follow up. Sensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw commonly occur after treatment with sumatriptan injection and are usually non-cardiac in origin.

ZEMBRACE SymTouch may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction, splenic infarction, and Raynaud’s syndrome. Overuse of acute migraine drugs may lead to exacerbation of headache (medication overuse headache). Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms may be necessary.

Serotonin syndrome may occur with ZEMBRACE SymTouch, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors. Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT1 agonists, including patients without a history of hypertension. Monitor blood pressure in patients treated with ZEMBRACE SymTouch. Discontinue ZEMBRACE SymTouch if serotonin syndrome is suspected or hypertensive crisis is observed.

Seizures have been reported following administration of sumatriptan. Some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures. ZEMBRACE SymTouch should be used with caution in patients with a history of epilepsy or conditions associated with a lowered seizure threshold.

Most common adverse reactions (≥5% and > placebo) were injection site reactions, tingling, dizziness/vertigo, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, flushing, feeling of tightness, and numbness.

These are not all the side effects associated with ZEMBRACE SymTouch. Advise the patient to read the FDA-approved patient labeling. Please see Patient Information, Instructions For Use and Full Prescribing Information for ZEMBRACE SymTouch at www.ZEMBRACE.com.

You are encouraged to report negative side effects of prescription drugs. To report SUSPECTED SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at 1-800-FDA-1088 (1-800-332-1088) or online at http://www.fda.gov/Safety/MedWatch

INDICATION AND USAGE

ZEMBRACE SymTouch is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use:
  • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with ZEMBRACE SymTouch, reconsider the diagnosis before ZEMBRACE SymTouch is administered to treat any subsequent attacks.
  • ZEMBRACE SymTouch is not indicated for the prevention of migraine attacks.